The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program
United European Gastroenterology Journal · 2023
DOI: 10.1002/ueg2.12422 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2023. Verfasst von Iris J M Levink und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Pancreatic Cyst. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population.
Methods
The PACYFIC‐registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow‐up of 12 months.
Results
Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow‐up of 25 months (IQR 24, 1966 visits), 29 participants developed high‐grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow‐up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1–13, p = 0.03).
Conclusions
In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false‐positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Surgery, Bologna University, Bologna, Italy.
- Department of Gastroenterology, Hepatology, and Clinical Oncology, Center of Postgraduate Medical Education, Warsaw, Poland.
- Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Iris J M Levink, Kasper A Overbeek, Rutger Quispel
Zitieren
APA
Levink, I. J. M., Jaarsma, S. C., Koopmann, B. D. M., van Riet, P. A., Overbeek, K. A., Meziani, J., Sprij, M. L. J. A., Casadei, R., Ingaldi, C., Polkowski, M., Engels, M. M. L., van der Waaij, L. A., Carrara, S., Pando, E., Vornhülz, M., Honkoop, P., Schoon, E. J., Laukkarinen, J., Bergmann, J. F., …, & PACYFIC-registry work group (2023). The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12422
Vancouver
Levink IJM, Jaarsma SC, Koopmann BDM, van Riet PA, Overbeek KA, Meziani J, et al. The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program. United European Gastroenterology Journal. 2023. doi:10.1002/ueg2.12422
BibTeX
@article{Levink2023,
author = {Levink, Iris J M and Jaarsma, Sanne C and Koopmann, Brechtje D M and van Riet, Priscilla A and Overbeek, Kasper A and Meziani, Jihane and Sprij, Marloes L J A and Casadei, Riccardo and Ingaldi, Carlo and Polkowski, Marcin and Engels, Megan M L and van der Waaij, Laurens A and Carrara, Silvia and Pando, Elizabeth and Vornhülz, Marlies and Honkoop, Pieter and Schoon, Erik J and Laukkarinen, Johanna and Bergmann, Jilling F and Rossi, Gemma and van Vilsteren, Frederike G I and van Berkel, Anne-Marie and Tabone, Trevor and Schwartz, Matthijs P and Tan, Adriaan C I T L and van Hooft, Jeanin E and Quispel, Rutger and van Soest, Ellert and Czacko, Laszlo and Bruno, Marco J and Cahen, Djuna L and PACYFIC-registry work group, PACYFIC-registry work group},
title = {The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program},
journal = {United European Gastroenterology Journal},
year = {2023},
doi = {10.1002/ueg2.12422}
}
EUVIMED